HSIC vs TAK
Henry Schein vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | HSIC | TAK |
|---|
| AI Score |
67
|
67
|
| Price |
$89.16
|
$17.49
|
| P/E Ratio |
25.77×
|
48.87×
|
| ROE |
12.3%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.3%
|
62.1%
|
| Debt / Equity |
1.21×
|
0.65×
|
| Dividend Yield |
0.0%
|
3.6%
|
| RSI (14) |
59.4
|
61.6
|
| Beta |
0.808
|
0.088
|
| Expected Upside |
+0.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for HSIC versus TAK.
The committee scores are tied.
HSIC and TAK both score 67/100.
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical